Differences in Chemotaxis of Human Mesenchymal Stem Cells and Cervical Cancer Cells

Overview

Journal Apoptosis

Publisher Springer

Date 2022 Jul 18

PMID 35849265

Authors

Yizuo Song

Ruyi Li

Miaomiao Ye

Chunyu Pan

Lihong Zheng

Zhi-Wei Wang

Xueqiong Zhu

Affiliations

Soon will be listed here.

Abstract

In the last decade, there has been a rapid expansion in tumor targeted therapy using mesenchymal stem cells (MSCs) based on their unique tropism towards cancer cells. Despite similarities in morphology, immunophenotype, and differential potent in vitro, MSCs originated from different tissues do not necessarily have equivalent biological behaviors. It is important to screen the most chemotactic MSCs to cancer cells. In this study, different MSCs were isolated from various human tissues including adipose, umbilical cord, amniotic membrane, and chorion. The chemotaxis of human MSCs to cervical cancer cells was measured by CCK-8, ELISA and Transwell invasion assays. Western blotting was performed to explore the underlying mechanisms. MSCs derived from distinct sources can be differently recruited to cervical cancer cells, among which chorion-derived MSC (CD-MSC) possessed the strongest tropic capacity. CXCL12 was found to be highly secreted by cervical cancer cells, in parallel with the expression of CXCR4 in all MSCs. CD-MSC displayed the highest level of CXCR4. These results indicated that CXCL12/CXCR4 pathway contributed to the different chemotaxis to cervical cancer cells of each MSCs. This study proposed that CD-MSC with the highest CXCR4 expression is a promising therapeutic vehicle for targeted therapy in cervical cancer.

Citing Articles

Cisplatin-encapsulated TRAIL-engineered exosomes from human chorion-derived MSCs for targeted cervical cancer therapy.

Ye M, Liu T, Miao L, Ji H, Xu Z, Wang H Stem Cell Res Ther. 2024; 15(1):396.

PMID: 39497209 PMC: 11536590. DOI: 10.1186/s13287-024-04006-6.

Mesenchymal Stem Cells Target Gastric Cancer and Deliver Epirubicin Tunneling Nanotubes for Enhanced Chemotherapy.

Zhou Y, Li Y, Wang H, Sun H, Su J, Fan Y Curr Stem Cell Res Ther. 2024; 19(10):1402-1413.

PMID: 38173205 DOI: 10.2174/011574888X287102240101060146.

Emerging role of mesenchymal stromal cells in gynecologic cancer therapy.

Song Y, Liu H, Pan S, Xiang X, Ye M, Zhu X Stem Cell Res Ther. 2023; 14(1):347.

PMID: 38049868 PMC: 10696729. DOI: 10.1186/s13287-023-03585-0.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Zhao F, Qiao Y . Cervical cancer prevention in China: a key to cancer control. Lancet. 2019; 393(10175):969-970. DOI: 10.1016/S0140-6736(18)32849-6. View

Bao H, Zhang L, Wang L, Zhang M, Zhao Z, Fang L . Significant variations in the cervical cancer screening rate in China by individual-level and geographical measures of socioeconomic status: a multilevel model analysis of a nationally representative survey dataset. Cancer Med. 2018; 7(5):2089-2100. PMC: 5943548. DOI: 10.1002/cam4.1321. View

Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J . Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2019; 8(2):e191-e203. PMC: 7025157. DOI: 10.1016/S2214-109X(19)30482-6. View

Wei M, Zhou W, Bi Y, Wang H, Liu Y, Zhang Z . Rising Mortality Rate of Cervical Cancer in Younger Women in Urban China. J Gen Intern Med. 2018; 34(2):281-284. PMC: 6374275. DOI: 10.1007/s11606-018-4732-z. View

Koh W, Abu-Rustum N, Bean S, Bradley K, Campos S, Cho K . Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(1):64-84. DOI: 10.6004/jnccn.2019.0001. View

Griffiths M, Winship A, Hutt K . Do cancer therapies damage the uterus and compromise fertility?. Hum Reprod Update. 2019; 26(2):161-173. DOI: 10.1093/humupd/dmz041. View

Spears N, Lopes F, Stefansdottir A, Rossi V, De Felici M, Anderson R . Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update. 2019; 25(6):673-693. PMC: 6847836. DOI: 10.1093/humupd/dmz027. View

Griffin M, Ritter T, Mahon B . Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther. 2010; 21(12):1641-55. DOI: 10.1089/hum.2010.156. View

10.

Pittenger M, Mackay A, Beck S, Jaiswal R, Douglas R, Mosca J . Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284(5411):143-7. DOI: 10.1126/science.284.5411.143. View

11.

Uccelli A, Moretta L, Pistoia V . Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2009; 8(9):726-36. DOI: 10.1038/nri2395. View

12.

Hu Y, Fu Y, Tabata Y, Gao J . Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J Control Release. 2010; 147(2):154-62. DOI: 10.1016/j.jconrel.2010.05.015. View

13.

Chulpanova D, Kitaeva K, Tazetdinova L, James V, Rizvanov A, Solovyeva V . Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor Treatment. Front Pharmacol. 2018; 9:259. PMC: 5869248. DOI: 10.3389/fphar.2018.00259. View

14.

Kemp K, Hows J, Donaldson C . Bone marrow-derived mesenchymal stem cells. Leuk Lymphoma. 2005; 46(11):1531-44. DOI: 10.1080/10428190500215076. View

15.

Rodriguez A, Elabd C, Amri E, Ailhaud G, Dani C . The human adipose tissue is a source of multipotent stem cells. Biochimie. 2005; 87(1):125-8. DOI: 10.1016/j.biochi.2004.11.007. View

16.

Ding D, Chang Y, Shyu W, Lin S . Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant. 2015; 24(3):339-47. DOI: 10.3727/096368915X686841. View

17.

camernik K, Mihelic A, Mihalic R, Marolt Presen D, Janez A, Trebse R . Skeletal-muscle-derived mesenchymal stem/stromal cells from patients with osteoarthritis show superior biological properties compared to bone-derived cells. Stem Cell Res. 2019; 38:101465. DOI: 10.1016/j.scr.2019.101465. View

18.

Reinisch A, Etchart N, Thomas D, Hofmann N, Fruehwirth M, Sinha S . Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood. 2014; 125(2):249-60. PMC: 4287636. DOI: 10.1182/blood-2014-04-572255. View

19.

Wu M, Zhang R, Zou Q, Chen Y, Zhou M, Li X . Comparison of the Biological Characteristics of Mesenchymal Stem Cells Derived from the Human Placenta and Umbilical Cord. Sci Rep. 2018; 8(1):5014. PMC: 5864926. DOI: 10.1038/s41598-018-23396-1. View

20.

Horwitz E, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini F . Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005; 7(5):393-5. DOI: 10.1080/14653240500319234. View